Literature DB >> 31711578

Viremia Negativization After BK Virus Infection in Kidney Transplantation: A National Bicentric Study.

Manuela Garofalo1, Francesco Pisani2, Quirino Lai1, Filippo Montali2, Francesco Nudo1, Aurelia Gaeta1, Gianluca Russo1, Andrea Natilli2, Luca Poli1, Caterina Martinelli2, Barbara Binda2, Renzo Pretagostini3.   

Abstract

BACKGROUND: BK virus (BKV) infection represents a potentially dreadful complication after kidney transplantation (KT). When BK viremia is detected, the best therapeutic approach remains not entirely clarified. Critical elements of BK viremia treatment are immunosuppression minimization and introduction of drugs like leflunomide, everolimus, and fluoroquinolones. The study aimed to analyze the results of the BK viremia management in 2 collaborative Italian centers.
METHODS: Ten patients undergoing KT in the 2 collaborative Italian centers of Sapienza University of Rome and University of L'Aquila from January 2013 to December 2017 and showing a post-KT diagnosis of BK viremia were retrospectively investigated.
RESULTS: Mean time from KT to BKV positivity was 7 months (range: 1-19 months). At diagnosis, the mean viral load was 683,842 copies/mL (range: 5800-4,052,415 copies/mL), with an average zenith of 2,428,410 copies/mL (range: 6762-18,022,500 copies/mL). In the 5 patients with BKV nephropathy, we observed a switch from antimetabolite to leflunomide (n = 5), a switch from tacrolimus to everolimus (n = 3), or an introduction of fluoroquinolones (n = 3). BKV clearance was achieved in 3 patients.
CONCLUSIONS: Early BKV diagnosis and stepwise minimization of immunosuppression remain the first-line approach in patients with BK viremia. In the presence of BKV nephropathy, a combination of antiviral drugs like leflunomide and fluoroquinolones/everolimus should favor viremia clearance.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31711578     DOI: 10.1016/j.transproceed.2019.04.091

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

Review 1.  Therapeutic Potential of Exploiting Autophagy Cascade Against Coronavirus Infection.

Authors:  Subhajit Maity; Abhik Saha
Journal:  Front Microbiol       Date:  2021-05-14       Impact factor: 5.640

2.  An Open Question: Is It Rational to Inhibit the mTor-Dependent Pathway as COVID-19 Therapy?

Authors:  Giuseppe Terrazzano; Valentina Rubino; Anna Teresa Palatucci; Angela Giovazzino; Flavia Carriero; Giuseppina Ruggiero
Journal:  Front Pharmacol       Date:  2020-05-29       Impact factor: 5.810

Review 3.  Pathogenicity of BK virus on the urinary system.

Authors:  Wojciech Krajewski; Dorota Kamińska; Adrian Poterek; Bartosz Małkiewicz; Jacek Kłak; Romuald Zdrojowy; Dariusz Janczak
Journal:  Cent European J Urol       Date:  2020-02-27

4.  Persistent BK Polyomavirus Viruria is Associated with Accumulation of VP1 Mutations and Neutralization Escape.

Authors:  Dorian McIlroy; Mario Hönemann; Ngoc-Khanh Nguyen; Paul Barbier; Cécile Peltier; Audrey Rodallec; Franck Halary; Emilie Przyrowski; Uwe Liebert; Maryvonne Hourmant; Céline Bressollette-Bodin
Journal:  Viruses       Date:  2020-07-29       Impact factor: 5.048

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.